2019年1月10日（周四）15:00 – 16:00 p.m.
Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy is effective for adenocarcinomatous non-small cell lung cancer patients in advanced stages with/without relapse or recurrence. However, not all of patients are sensitive to anti-EGFR therapy and even the best cases finally become refractory to this therapy. Therefore, discovery of a new combination strategies and novel mechanisms that contribute to both primary and acquired anti-EGFR therapy resistance to overcome or reverse this resistance is imperative. In this talk, Dr. Xi Zhang will characterize the anti-cancer efficacy of specific BAD phosphorylation inhibitor---NPB, and analyze the synergistic rationalities of combination strategies.
Xi Zhang, received her Ph.D. degree in Medicine from University of Munich (LMU), Germany, in 2018. Afterwards Dr. Xi Zhang joined Postdoctoral in the Precision Medicine and Healthcare Research Center, Tsinghua-Berkeley Shenzhen Institute, supervised by Prof. Peter E. Lobie. She has exceptionally experienced and proficient in her specialized area, including gynaecology, tumor biology, chemoprevention of cancer and inflammation-related diseases, and target therapy.